Feasibility and Efficacy of Chemoradiotherapy for Elderly Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: Results from a Matched Cohort Analysis
Huai Liu,Qiu-Yan Chen,Ling Guo,Lin-Quan Tang,Hao-Yuan Mo,Zong-Liang Zhong,Pei-Yu Huang,Dong-Hua Luo,Rui Sun,Xiang Guo,Ka-Jia Cao,Ming-Huang Hong,Hai-Qiang Mai
DOI: https://doi.org/10.1186/1748-717x-8-70
IF: 4.309
2013-01-01
Radiation Oncology
Abstract:Background To clarify the feasibility and efficacy of chemoradiotherapy (CRT) in elderly (age≥65 years) patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Methods From January 2000 to December 2006, 101 newly diagnosed elderly non-metastatic NPC patients (age≥65 years) who received cisplatin 3-weekly or weekly concurrent CRT with/without sequential chemotherapy were recruited. Each patient from the CRT group was matched to another patient treated with radiotherapy (RT) alone based on age, gender, pathological type, performance status, overall stage, stage method, Adult Comorbidity Evaluation-27 (ACE-27) score and RT technique, from the same institute and time period. We also recruited 101 young patients (age<65 years) as the referent group, which had been matched to the CRT group based on patient characteristics and treatment parameters. Treatment tolerability and toxicity were clarified, and treatment outcomes were calculated and compared among groups. Results CRT was feasible in elderly NPC patients, while a concurrent regimen of weekly cisplatin was more tolerable. Grade≥3 acute toxicity in CRT group was similar with referent group, although it was significantly higher than the RT alone group (65.3% vs. 43.6%, P =0.002). Furthermore, patients with ACE-27 score≥2 in the CRT group had significantly higher severe acute toxicity and dose reduction. Survival was poorer in elderly patients than the referent group. Compared to RT alone, CRT significantly improved the 5-year overall survival (OS: 54.6% vs. 39.3%, P =0.009), cancer-specific survival (CSS: 56.6% vs. 42.7%, P =0.022), disease-free survival (DFS: 51.6% vs. 30.2%, P =0.028) and locoregional relapse-free survival (LRRFS: 78.4% vs. 52.2%, P =0.003), but not distant metastasis-free survival (DMFS: 69.6% vs. 63.6%, P =0.669). However, CRT did not significantly improve 5-year OS (43.6% vs. 27.3%, P =0.893) or CSS (43.6% vs. 34.1%, P =0.971) in elderly NPC patients with ACE-27 score≥2. Conclusions CRT is feasible and effective in elderly patients with locoregionally advanced NPC without severe comorbidities. CRT should be used under serious consideration and be further tested in elderly patients with severe comorbidities. As such, it is essential to perform a comprehensive evaluation of pretreatment comorbidity status for all elderly NPC patients.